文献速递术前评估与围术期医学疼痛医学

地塞米松与术后6个月伤口疼痛:PADDI随机试验预设分析

Dexamethasone and persistent wound pain: a prespecified analysis of the randomised Perioperative Administration of Dexamethasone and Infection (PADDI) trial.
PubMed 文献 · Br J Anaesth · 2023-05-23

该预设优势子研究基于PADDI随机试验,比较非急诊非心脏手术患者诱导后静脉给予地塞米松8 mg或安慰剂对术后6个月伤口疼痛的影响。纳入改良意向治疗人群8478例(地塞米松组4258例,匹配安慰剂组4220例)。结果显示地塞米松组6个月伤口疼痛发生率11.5%,安慰剂组9.6%(RR 1.2,95%CI 1.06-1.41,P=0.003),提示地塞米松8 mg与术后6个月伤口疼痛风险增加相关。

要点

  • 地塞米松8 mg静脉给药与术后6个月伤口疼痛风险增加相关(RR 1.2)。
  • 术后前3天静息和活动疼痛评分地塞米松组较低,但未转化为慢性疼痛获益。
  • 术后急性疼痛严重程度不能预测慢性术后疼痛。

核心结论

  • 诱导后静脉给予地塞米松8 mg与术后6个月手术伤口疼痛风险增加相关。
  • 地塞米松组6个月伤口疼痛发生率11.5%,安慰剂组9.6%(RR 1.2,95%CI 1.06-1.41,P=0.003)。

研究设计与样本

  • PADDI随机试验的预设嵌入式优势子研究,患者接受非急诊非心脏手术。
  • 诱导后静脉给予地塞米松8 mg或安慰剂,随访至术后6个月。
  • 改良意向治疗人群8478例:地塞米松组4258例,匹配安慰剂组4220例。

主要发现

  • 主要结局(术后6个月手术伤口疼痛)地塞米松组491例(11.5%),安慰剂组404例(9.6%)。
  • 术后前3天静息疼痛评分中位数地塞米松组5(IQR 3.0-8.0)vs 安慰剂组6(IQR 3.0-8.0),P<0.001。
  • 术后前3天活动疼痛评分中位数地塞米松组7(IQR 5.0-9.0)vs 安慰剂组8(IQR 6.0-9.0),P<0.001。
  • 术后疼痛严重程度不能预测慢性术后疼痛。
  • 慢性术后疼痛严重程度和神经病理性特征频率两组无差异。

关键数值与推荐

  • 地塞米松剂量为8 mg静脉给药,诱导后给予。
  • 主要结局为术后6个月手术伤口疼痛发生率。
  • 慢性术后疼痛严重程度和神经病理性特征频率两组无差异。

临床怎么用

  • 围术期使用地塞米松8 mg预防术后恶心呕吐时,应知晓其与术后6个月伤口疼痛风险增加相关。
  • 不应期望地塞米松8 mg降低慢性术后疼痛风险。
  • 术后急性疼痛严重程度不宜用于预测慢性术后疼痛。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dexamethasone is commonly administered intraoperatively to prevent postoperative nausea and vomiting and is believed to have analgesic properties. It is unknown whether it has an impact on chronic wound pain. METHODS: In this prespecified embedded superiority substudy of the randomised PADDI trial, patients undergoing non-urgent noncardiac surgery received dexamethasone 8 mg or placebo intravenously after induction of anaesthesia, and were followed up for 6 months postoperatively. The primary outcome was the incidence of pain in the surgical wound at 6 months. Secondary outcomes included acute postoperative pain and correlates of chronic postsurgical pain. RESULTS: We included 8478 participants in the modified intention-to-treat population (4258 in the dexamethasone group and 4220 in the matched placebo group). The primary outcome occurred in 491 subjects (11.5%) in the dexamethasone arm and 404 (9.6%) subjects in the placebo arm (relative risk 1.2, 95% confidence interval 1.06-1.41, P=0.003). Maximum pain scores at rest and on movement in the first 3 postoperative days were lower in the dexamethasone group compared with the control group {median 5 (inter-quartile range [IQR] 3.0-8.0) vs 6 (IQR 3.0-8.0) and median 7 (IQR 5.0-9.0) vs 8 (IQR 6.0-9.0), P<0.001 for both}. Severity of postoperative pain was not predictive of chronic postsurgical pain. The severity of chronic postsurgical pain and the frequency of neuropathic features did not differ between treatment groups. CONCLUSION: Administration of dexamethasone 8 mg i.v. was associated with an increase in the risk of pain in the surgical wound 6 months after surgery. CLINICAL TRIAL REGISTRATION: ACTRN12614001226695.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Corcoran TB, Martin C, O'Loughlin E, et al. Dexamethasone and persistent wound pain: a prespecified analysis of the randomised Perioperative Administration of Dexamethasone and Infection (PADDI) trial. Br J Anaesth. 2023. PMID: 37230849. doi:10.1016/j.bja.2023.03.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。